FDA Clearance Tracker · P150025-S014
PD-L1 IHC 28-8 pharmDx
Last checked: Nov 20, 2026Latest source record: Oct 18, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Oct 18, 2021
Approved
Time to decision
98 days
Received Jul 12, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150025-S014
- Device name
- PD-L1 IHC 28-8 pharmDx
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Jul 12, 2021
- Decided
- Oct 18, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150025
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to update the current approved urothelial carcinoma (UC) indication of PD-L1 IHC 28-8 pharmDx: to include enhanced disease-free survival and new clinical data from Bristol-Myers Squibb (BMS) clinical study CA209274 (CHECKMATE-274) in this existing indication.PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity.Companion Diagnostic IndicationTumor Indication PD-L1 ExpressionClinical Cutoff Intended UseNSCLC >= 1% tumor cell expression PD-L1 ICH 28-8 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).When used in accordance with approved therapeutic labeling:PD-L1 expression (>= 1% or >= 5% or >= 10% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC (nsNSCLC) may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in SCCHN may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in UC may be associated with enhanced response rate and enhanced disease-free survival from OPDIVO®.See the OPDIVO® and YERVOY® product labels for specific clinical circumstances guiding PD-L1 testing.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.